LARGE-SCALE PRODUCTION & PURIFICATION OF COMPOUNDS WITH BIOLOGICAL ACTIVITY

大规模生产

• 批准号: 5201906
• 负责人: J SHILOACH
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5201906
• 关键词: antigens; bacterial toxins; biotechnology; chemical registry /resource; immunological substance; malaria vaccines; microorganism mass culture; microorganism resource /registry; protein purification; tissue /cell culture

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large-scale growth of procaryotic cells and eucaryotic cells, production of various compounds from microorganisms and eucaryotic cells, and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Unit is capable of handling various production problems associated with widely different topics. The Unit performs this task by implementing both physiological and technical approaches. Efficient process development and production is possible to perform since the Unit possesses two integrated elements: fully operational multi-purpose pilot production facility and the capability of conducting research and development. During the last 12 months the Unit performed 200 different large-scale preparations. The Unit continues its effort to produce large amounts of proteins needed for various clinical use: S antigen from bovine retina, currently in the second phase of the clinical trials, and several modified bacterial protein toxins needed for the preparation of conjugated vaccines. The facility continues to prepare large quantities of various mammalian cells and start a project for the production of a transmission-blocking vaccine for malaria.

生物技术单位负责生产和提纯 生物材料。该股承担了广泛的生物 生产任务，如大规模培养原核细胞和 真核细胞，从微生物中生产各种化合物和 真核细胞，特别是生物化合物的纯化 蛋白质。这些产品不是商业来源的，它们是 用于临床和结构研究。 该股有能力处理各种相关的生产问题 主题大相径庭。该股执行这项任务的方式是执行 无论是生理方法还是技术方法。高效流程 可以进行开发和生产，因为该单位拥有 两个综合要素：全面运作的多用途试生产 设施和进行研发的能力。 在过去12个月中，该股进行了200次不同的大规模 准备工作。 该股继续努力生产所需的大量蛋白质 各种临床用途：来自牛视网膜的S抗原，目前在 第二阶段的临床试验，以及几种改良的细菌 制备结合疫苗所需的蛋白质毒素。这个 该设施继续准备大量的各种哺乳动物细胞 并启动一个生产传播阻断疫苗的项目 治疗疟疾。